1,2,3,4-Tetrahydro-1-(3,4,5-trimethoxyphenyl)-6,7-isoquinolinediol hydrochloride | 18559-63-2

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 异喹啉及其衍生物
• 英文名称: 1,2,3,4-Tetrahydro-1-(3,4,5-trimethoxyphenyl)-6,7-isoquinolinediol hydrochloride
• 英文别名: 1-[(3,4,5-trimethoxyphenyl)methyl]-1,2,3,4-tetrahydroisoquinolin-2-ium-6,7-diol;chloride
• CAS: 18559-63-2
• 化学式: C19H24ClNO5
• 分子量: 381.8
• InChiKey: UHSXRTHJCJGEKG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -1.47
• 重原子数：
  26
• 可旋转键数：
  5
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.37
• 拓扑面积：
  84.8
• 氢给体数：
  3
• 氢受体数：
  6

文献信息

• TROPAN COMPOUND
  申请人：ONO PHARMACEUTICAL CO., LTD.

  公开号：EP1785421A1

  公开（公告）日：2007-05-16

  The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse ractions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R1, R2, R3 and R1 each a hydrogen atom or a substituent; R5 is a substituent; X- is an anion;the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

  传统的抗胆碱药物通过吸入给药被认为可能加重与前列腺增生相关的排尿困难，并要求传统的抗胆碱药物通过吸入给药必须显示减少副作用或不良反应。 本发明涉及一种由通式（I）表示的化合物： （其中A代表; 和R1、R2、R3和R1分别是氢原子或取代基; R5是取代基; X-是阴离子;符号: 表示外向型或内向型，或它们的混合物），其盐或溶剂化产物。它们可用作通过胆碱受体介导的疾病的预防和/或治疗剂，具有减少副作用或不良反应。
• Beta3-Adrenoreceptor agonists, agonist compositions and methods of using
  申请人：Feller R. Dennis

  公开号：US20050096347A1

  公开（公告）日：2005-05-05

  The invention provides β 3 -adrenoreceptor agonists, pharmaceutical compositions comprising β 3 -adrenoreceptor agonist compounds, and methods of using such compounds for stimulating, regulating or modulating metabolism of fats in adipose tissue in animals.

  本发明提供了β3肾上腺素能受体激动剂，包括β3肾上腺素能受体激动剂化合物的制药组合物，并提供使用这种化合物来刺激、调节或调节动物脂肪代谢的方法。
• β3-Adrenoreceptor agonists, agonist compositions and methods of using
  申请人：Molecular Design International, Inc.

  公开号：US07119103B2

  公开（公告）日：2006-10-10

  The invention provides β3-adrenoreceptor agonists, pharmaceutical compositions comprising β3-adrenoreceptor agonist compounds, and methods of using such compounds for stimulating, regulating or modulating metabolism of fats in adipose tissue in animals.

  本发明提供了β3-肾上腺素能受体激动剂、包含β3-肾上腺素能受体激动剂化合物的药物组合物以及使用这些化合物刺激、调节或调节动物脂肪组织代谢的方法。
• &bgr;3-adrenoreceptor agonists, agonist compositions and methods of using
  申请人：Molecular Design International, Inc.

  公开号：US06825213B2

  公开（公告）日：2004-11-30

  The invention provides &bgr;3-adrenoreceptor agonists, pharmaceutical compositions comprising &bgr;3-adrenoreceptor agonist compounds, and methods of using such compounds for stimulating, regulating or modulating metabolism of fats in adipose tissue in animals.

  本发明提供β3-肾上腺素受体激动剂、包含β3-肾上腺素受体激动剂化合物的制药组合物，以及使用这些化合物刺激、调节或调节动物脂肪在脂肪组织中的代谢的方法。
• Tropane Compounds and Pharmaceutical Compositions Comprising the Same as an Active Ingredient
  申请人：Nakai Hisao

  公开号：US20080027094A1

  公开（公告）日：2008-01-31

  The conventional anticholinergic drugs for administration through inhalation have been considered to have the possibility of aggravating dysuria associated with prostatic hyperplasia mediated by blood, and it has been demanded that the conventional anticholinergic drugs for administration through inhalation will have to show reduced side effects or adverse reactions. The present invention relates to a compound represented by the general formula (I): (wherein A represents; and R 1 , R 2 , R 3 and R 1 each a hydrogen atom or a substituent; R 5 is a substituent; X − is an anion; the symbol: denotes an exo-form or endo-form, or their mixture), its salt or solvation product thereof. They are useful as a prophylactic and/or therapeutic agent with reduced side effects or adverse reactions for the diseases mediated by the muscarinic receptor.

  传统的通过吸入途径给药的抗胆碱药物被认为可能会加重与前列腺增生有关的排尿困难，因此要求传统的通过吸入途径给药的抗胆碱药物必须显示出减少的副作用或不良反应。本发明涉及一种由通式（I）表示的化合物：（其中A表示；R1、R2、R3和R4分别表示氢原子或取代基；R5表示取代基；X-表示阴离子；符号：表示外部形式或内部形式，或它们的混合物），其盐或溶剂化产物。它们可用作具有减少副作用或不良反应的预防和/或治疗剂，用于由肌肉性受体介导的疾病。